Blog

Results from a meta-analysis in CLL: model supports MRD as primary endpoint in CLL chemo-immunotherapy trials – Lymphoma Hub


Lymphoma Hub

Results from a meta-analysis in CLL: model supports MRD as primary endpoint in CLL chemo-immunotherapy trials
Lymphoma Hub
This analysis was done to determine whether the treatment effect on MRD response in PB at the end of induction treatment with chemo-immunotherapy can predict treatment effect on PFS in patients with CLL. To this end, the investigators employed PB- MRD

2018-01-19 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.